Thermo Fisher Scientific is set to acquire QIAGEN N.V. for $11.5B including the assumption of $1.4b in debt in the second major U.S. healthcare acquisition this week.
“This acquisition provides us with the opportunity to leverage our industry-leading capabilities and R&D expertise to accelerate innovation and address emerging healthcare needs. For shareholders, we expect the transaction to be immediately accretive and to generate significant cost and revenue synergies.”
Marc Casper, Thermo Fisher Chairman and CEO
QIAGEN is a leading provider of life science and molecular diagnostic solutions. They will expand Thermo Fishers speciality diagnostic portfolio to include molecular diagnostic capabilities and infectious disease testing.